# 2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC

- Source: PR Newswire
- Published: 2026-10-25T06:00:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/2026-esmo--innovent-presented-phase-1-study-data-for-ibi3001-a-first-in-class-egfrb7h3-bispecific-adc-302918633.html
- Canonical: https://groundlevelnews.com/story/2026-esmo-innovent-presented-phase-1-study-data-for-ibi3001-a-first-in-a102b1/

SAN FRANCISCO and SUZHOU, China, Oct. 25, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune,...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire._